Opinion
Lilly blood thinner tops AstraZeneca’s for heart procedure diabetes patients
The number of adults living with diabetes worldwide has surpassed 800mn, more than quadrupling since 1990. Most of them are between the ages of 20 and 79
November 15, 2025 | 11:35 PM
Blood-thinning drugs that doctors often prescribe interchangeably after procedures to reopen narrowed heart arteries don’t work equally well in patients with diabetes, a study from India found.All 1,800 study participants had Type 1 or Type 2 diabetes, and all had undergone minimally invasive interventions to clear a clogged coronary artery and prop it open using a drug-coated stent to help reduce the risk of reclogging.Afterward, they received aspirin plus either AstraZeneca’s Brilinta (ticagrelor) or Effient (prasugrel), sold by Eli Lilly and Daiichi Sankyo, from a class of drugs known as P2Y12 inhibitors that are prescribed to prevent the formation of blood clots.The combined rate of heart attack, stroke, bleeding complications or death was 16.6% in the ticagrelor group and 14.2% in the prasugrel group, researchers reported at the recent American Heart Association Scientific Sessions in New Orleans.Patterns were similar when rates of non-fatal heart attack, major bleeding, and death were analysed separately."For individuals with Type 1 or Type 2 diabetes and complex coronary disease, there may be an advantage to treatment with prasugrel over ticagrelor,” study leader Dr Sripal Bangalore of the NYU Grossman School of Medicine said in a statement."We were surprised by the results because we hypothesised that ticagrelor should be as good or perhaps even better than prasugrel,” he said. "It’s important to choose the right medicine, and at least from our data, we cannot say that ticagrelor and prasugrel are interchangeable.”General anaesthesia is a reasonable option for women giving birth via caesarean section, especially when spinal or epidural nerve blocks are ineffective, a new analysis shows.Up to one in six women who receive regional anaesthesia during a caesarean section may feel pain, and for some, the pain can be excruciating, but general anaesthesia has long been avoided due to concerns about its effects on the baby, researchers noted in a report of their study in Anesthesiology.They analysed 30 years of data from dozens of randomised trials involving nearly 3,500 infants born via caesarean section. Roughly half of the surgeries were done with general anaesthesia.While babies born under spinal or epidural anaesthesia had slightly higher Apgar scores — a measure of newborn health — than those born under general anaesthesia, the differences were small and not likely to be clinically meaningful, the researchers found.They also found that babies born under general anaesthesia were slightly more likely to need breathing support immediately after birth, but there was no increase in neonatal ICU admissions.The research does not suggest that general anaesthesia should replace localised techniques, but it can be a reasonable option in certain cases, the authors said."Since regional anaesthesia is so widely used, it’s common for patients to feel that a spinal or epidural block is the only safe option for caesarean section,” study leader Dr Mark Neuman of the Perelman School of Medicine at the University of Pennsylvania said in a statement. "But as our study shows, anaesthesia type during pregnancy does not need to be one-size-fits-all.”According to the International Diabetes Federation and the World Health Organisation (WHO), the number of adults living with diabetes worldwide has surpassed 800mn, more than quadrupling since 1990. Most of them are between the ages of 20 and 79 worldwide. It is estimated that about 43% of people with diabetes are unaware of their condition, putting them at risk of serious complications, even though the disease can often be managed early. Projections also indicate that nearly 81% of people with diabetes live in low- and middle-income countries.Statistics show that in 2024, global diabetes-related health expenditure surpassed $1tn.
November 15, 2025 | 11:35 PM